Michael Ison: Highlights from IDWeek 2022

In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals and antibiotics.

Interviews available in this series:

Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates

Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results

Disclosures: Michael Ison receives grant/research support from GSK.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek 2022